Results 131 to 140 of about 128,389 (322)

Phase Separation: A New Dimension to Understanding Tumor Biology and Therapy

MedComm – Oncology, Volume 4, Issue 2, June 2025.
Liquid–liquid phase separation (LLPS) facilitates the assembly of biomolecular condensates by leveraging weak multivalent interactions. The low‐complexity domains, foldable domains of proteins, and nucleic acids provide multivalent interaction sites among different molecules and contribute to the formation of condensates.
Xingwen Wang, Minqiao Lu, Yi Zhang, Jiangwen Ma, Ying Hu   +4 more
wiley   +1 more source

ROLE OF BREAK CLUSTER REGION (BCR) - ABELSON MURINE LEUKIMIA (ABL) EXAMINATION IN CHRONIC MYELOGENOUS LEUKEMIA (CML)

Indonesian Journal of Tropical and Infectious Disease, 2015
Chronic myelogenous leukemia (CML) is a clonal bone marrow stem cell disorder associated with a characteristic chromosomal translocation called the Philadelphia chromosome which caused a proliferation of mature granulocytes (neutrophils, eosinophils and ...
Agung Sosiawan
doaj   +1 more source

Persistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-abl sequences in blast crisis. [PDF]

, 1986
Claus R. Bartram, Johannes W.G. Janssen, R. Becher, Annelies de Klein, Gerard C. Grosveld   +4 more
openalex   +1 more source

BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib fail [PDF]

, 2009
Imatinib is the standard treatment for chronic myeloid leukaemia. BCR-ABL kinase domain mutation is the commonest mechanism implicated in imatinib resistance. In in-vitro studies, kinase domain mutations are variably resistant to second-line agents.
Chan, YY, Kwan, TK, Lie, AKW, Liu, HSY, Ma, ESK, Sim, JPY, Wan, TSK, Yeung, YM, Yip, SF   +8 more
core  

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.

Blood, 2013
The response of Philadelphia chromosome (Ph(+)) acute lymphoblastic leukemia (ALL) to treatment by BCR-ABL tyrosine kinase inhibitors (TKIs) has been disappointing, often resulting in short remissions typified by rapid outgrowth of drug-resistant clones.
B. Koss, J. Morrison, Rhonda M. Perciavalle, Harpreet Singh, J. Rehg, R. Williams, J. Opferman   +6 more
semanticscholar   +1 more source

Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 6, Page 1050-1064, June 2025.
ABSTRACT This study investigates the impact of obesity on imatinib pharmacokinetics in cancer patients by utilizing physiologically based pharmacokinetic modeling (PBPK) and virtual clinical trial approaches and evaluates the effectiveness of therapeutic drug monitoring (TDM)–guided dose adjustment to recover the imatinib trough concentration (Cmin ...
Khairulanwar Burhanuddin, Afzal Mohammed, Nurul Afiqah Burhanuddin, Raj K. S. Badhan   +3 more
wiley   +1 more source

A Requirement for SOCS-1 and SOCS-3 Phosphorylation in Bcr-Abl-Induced Tumorigenesis

Neoplasia: An International Journal for Oncology Research, 2012
Suppressors of cytokine signaling 1 and 3 (SOCS-1 and SOCS-3) are inhibitors of the Janus tyrosine kinase (JAK)/signal transducers and activators of transcription (STAT) pathway and function in a negative feedback loop during cytokine signaling.
Xiaoxue Qiu, Guijie Guo, Ke Chen, Masaki Kashiwada, Brian J. Druker, Paul B. Rothman, Ji-Long Chen   +6 more
doaj   +1 more source

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia [PDF]

, 2008
The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CML) and is the standard front-line therapy for patients in chronic phase.
Anderson S M, Baccarani M, Bedi A, Cortes J, Danhauser-Riedl S, Dombret H, Donato N J, Druker B J, Engelman A, Gambacorti C, Hochhaus A, Ilaria R L, Kantarjian H M, Kieslinger M, Larson R, Lee F Y, Martinelli G, Nagar B, Overell R W, Pear W S, Puil L, Quintas-Cardama A, Shaoguang Li, Talpaz M, Watson J D   +24 more
core   +2 more sources

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

Leukemia, 2013
Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies.
M. Scherr, A. Elder, K. Battmer, D. Barzan, S. Bomken, M. Ricke-Hoch, A. Schro¨der, L. Venturini, H. Blair, J. Vormoor, O. Ottmann, A. Ganser, A. Pich, D. Hilfiker-Kleiner, O. Heidenreich, M. Eder   +15 more
semanticscholar   +1 more source

A Case of Stevens–Johnson Syndrome Induced by Selpercatinib

The Journal of Dermatology, Volume 52, Issue 6, Page 1066-1069, June 2025.
ABSTRACT Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis are fatal adverse skin reactions characterized by high fever, epidermal detachment, and mucositis. Selpercatinib is a highly selective inhibitor of tyrosine kinase, rearranged during transfection (RET), and is the first targeted therapy for solid tumors with RET gene alteration. The
Yuki Tone, Mami Matsui, Aeri Park, Saki Otani, Mizuki Shiba, Fumisa Okano, Iwao Sugitani, Naoko Kanda, Hidehisa Saeki, Toshihiko Hoashi   +9 more
wiley   +1 more source